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Trends in AIDS-Defining
and Non–AIDS-Defining
Malignancies among HIV-Infected
Patients: 1989–2002
Roger Bedimo, Ray Y. Chen, Neil A. Accortt, James L. Raper,
Carol Linn, Jeroan J. Allison, John Dubay, Michael S. Saag,
and Craig J. Hoesley
University of Alabama at Birmingham
In a comparison of rates of acquired immunodeficiency syn-
drome (AIDS)–defining malignancies (ADMs) for 1989–1996
versus 1997–2002, we found a decrease in ADMs (rate ratio,
0.31; ) and a significant increase in non–AIDS-P ! .0001
defining malignancies (non-ADMs; rate ratio, 10.87; P !
). The mean CD4 cell count was lower among patients.0002
with ADMs than among those with non-ADMs. A longer
duration of survival during highly active antiretroviral ther-
apy might explain the increasing incidence of non-ADMs.
Since the early days of the AIDS epidemic, HIV-infected pa-
tients have had an increased propensity to develop malignancies
[1–4]. In the HAART era, the spectrum of neoplasias in HIV-
infected patients has been changing, with a decrease in the rate
of AIDS-defining malignancies (ADMs). However, the rate of
non–AIDS-defining malignancies (non-ADMs) is reported to
be unchanged [5–7]. An increase in the incidence of non-ADM
has even been predicted, given the increased duration of sur-
vival among HIV-infected patients [8], but this has not been
observed in most studies [5, 9, 10].
Methods. A prospective, computerized database of infor-
mation on HIV-infected adults (known as the Studies of HIV/
AIDS Longitudinal Outcome Metrics [SHALOM] cohort),
which is followed at the University of Alabama at Birmingham
HIV Clinic (Birmingham, AL), was used to identify patients
with ADMs and non-ADMs diagnosed during the period of
January 1989 through August 2002. Demographic, laboratory,
and treatment data were analyzed. HAART was defined as an
Received 11 April 2004; accepted 24 June 2004; electronically published 11 October 2004.
Reprints or correspondence: Dr. Roger Bedimo, 4500 South Lancaster Rd., 111-D, Dallas,
TX 75216 (roger.bedimo@med.va.gov).
Clinical Infectious Diseases 2004; 39:1380–4
 2004 by the Infectious Diseases Society of America. All rights reserved.
1058-4838/2004/3909-0016$15.00
antiretroviral regimen that contained 1 protease inhibitor or
1 nonnucleoside reverse-transcriptase inhibitor.
The time from the first clinic visit to the date of cancer
diagnosis (for patients with cancer) or to the date in the da-
tabase on which the person was last known to be alive (for
patients without cancer) was calculated in person-years. Inci-
dence rates are presented as the number of cases per 1000
person-years. Rate ratios (RRs) and the corresponding 95% CIs
were calculated, comparing the incidence rates from 1989–1996
(the pre-HAART era) with the incidence rates from 1997–2002.
Comparisons of categorical variables were performed using
the x2 test, and comparisons of continuous variables were per-
formed using the Wilcoxon rank sum test. Cancer rates were
not adjusted for age, race, or sex, because the population served
by our clinic did not significantly change during the period of
observation.
Results. From September 1989 through August 2002, a
total of 2882 patients were observed at the University of Ala-
bama at Birmingham HIV Outpatient Clinic. For the analysis
of cancer incidences among these patients, 2 time periods were
chosen to represent the period before the availability and wide-
spread use of HAART (the pre-HAART era; 1989–1996) and
the period during which use of HAART was widespread (the
HAART era; 1997–2002). A total of 2882 patients were studied,
comprising 7452 person-years of follow-up (2994 person-years
of follow-up for 1989–1996 and 4458 person-years of follow-
up for 1997–2002).
There were a total of 227 incident cases of malignancies
diagnosed. Among them were 178 ADMs (109 cases of Kaposi
sarcoma, 64 cases of non-Hodgkin lymphoma, and 5 cases of
invasive cervical cancer) and 60 non-ADMs (including 11 cases
of Hodgkin disease, 18 cases of skin cancer, 9 cases of invasive
anal cancer, 13 cases of colon cancer, 3 cases of lung cancer, 2
cases of breast cancer, 1 case of lung cancer, 1 case of kidney
cancer, and 1 case of head and neck cancer). Most cases of skin
cancer were basal cell carcinoma (16 of 18 cases), with 1 case
of squamous cell cancer and 1 case of Merkel cell carcinoma.
The descriptive statistics for patients with cancer and those
without cancer are presented in table 1.
When comparing subjects who had ADMs with those who
had non-ADMs, we found no difference in the median age at
diagnosis of cancer (36.0 vs. 37.0 years), male sex (93.1% vs.
90.0%), white race (73.4% vs. 68.3%), or mode of acquisition
of HIV infection (86.0% vs. 81.3% were men who have sex
with men) (table 2).
In the overall study population, 63.0% of the patients were
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Table 1. Characteristics of HIV-infected patients with cancer and those without
cancer.
Characteristic
All patients
(n p 2882)
Patients
with cancer
(n p 227)
Patients
without cancer
(n p 2655) Pa
White race 59.5 72.3 58.4 !.0001
Male sex 80.2 92.1 79.2 !.0001
Man who has sex with men 68.4 85.4 66.9 !.0001
Injection drug user 13.6 17.4 13.3 .1
Receipt of HAARTb 63.0 30.7 66.2 !.0001
Nadir CD4 cell count during
follow-up, median cells/mL 116.0 36.0 129.0 !.0001
Agec
Median, in years 35.0 36.0 34.0 .0002
20–34 years 49.7 42.7 50.3
35–54 years 46.6 51.1 46.2
55 years 3.7 6.2 3.5 .01
NOTE. Data are percentage of patients, unless otherwise indicated.
a Comparison of patients with cancer and those without cancer.
b Percentage of patients receiving HAART at any time during the year preceding diagnosis of cancer.
c Age recorded at clinic enrollment.
Table 2. Characteristics of HIV-infected patients with cancer.
Characteristic
Cancer type
Pa
All
(n p 227)
ADM
(n p 178)
Non-ADM
(n p 49)
White race 72.3 73.4 68.3 .5
Male sex 92.1 93.1 90.0 .6
Man who has sex with men 85.4 86.0 81.3 .4
Injection drug user 17.4 20.5 10.0 .1
Receipt of HAARTb 30.7 20.0 58.2 !.0001
Duration of HAART, median daysc 309.5 71.5 437.0 .0007
Nadir CD4 cell count during
follow-up, median cells/mL 36.0 22.0 78.0 .0002
CD4 cell count before diagnosis
of cancer, median cells/mLd 93.0 37.5 276.5 !.0001
Agee
Median, in years 36.0 36.0 37.0 .05
20–34 years 42.7 45.7 33.3
35–54 years 51.1 49.1 58.3
55 years 6.2 5.2 8.3 .2
NOTE. Data are percentage of patients, unless otherwise indicated. ADM, AIDS-defining
malignancy.
a Comparison of patients with ADMs and those with non-ADMs.
b Percentage of patients receiving HAART at any time during the year preceding cancer
diagnosis.
c Median total number of days receiving HAART prior to cancer diagnosis.
d CD4 cell count within 90 days before cancer diagnosis.
e Age recorded at clinic enrollment.
receiving HAART during part or all of the follow-up period,
and the median nadir CD4 cell count was 116.0 cells/mL. Pa-
tients with cancer were less likely to be receiving HAART in
the year preceding diagnosis of cancer than were patients with-
out cancer (30.7% vs. 66.2%; ) (table 1). In the cohortP ! .0001
of patients with cancer, patients with ADMs had a lower mean
nadir CD4 cell count (22 vs. 78 cells/mL; ) and a muchPp .02
lower mean CD4 cell count at the time of cancer diagnosis (38
vs. 277 cells/mL; ), compared with those who had non-P ! .0001
ADMs. Patients with ADMs were less likely than those with
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Figure 1. Trends in the incidence of cancer among HIV-infected patients. Anal ca, anal cancer; CC, cervical cancer; HD, Hodgkin disease; KS,
Kaposi sarcoma; NHL, non-Hodgkin lymphoma; Skin, skin cancer.
Table 3. Trends in malignancies among HIV-infected patients.
Type of cancer
Annual incidence
(no. of cases)a
RR (95% CI) P1989–1996 1997–2002
AIDS-defining malignancy 39.91 (121) 11.33 (57) 0.31 (0.22–0.42) !.0001
Non-Hodgkin lymphoma 11.09 (34) 6.40 (30) 0.58 (0.35–0.94) .03
Kaposi sarcoma 27.82 (84) 5.41 (25) 0.19 (0.12–0.30) !.0001
Cervical cancer 6.36 (3) 2.01 (2) 0.32 (0.05–1.89) .2
Non-AIDS-defining 3.27 (10) 10.87 (50) 3.32 (1.69–6.55) .0002
Hodgkin disease 1.31 (4) 1.49 (7) 1.14 (0.33–3.89) .8
Skin cancer 0.33 (1) 3.64 (17) 11.18 (1.49–84.04) .003
Anal cancer 0.00 (0) 1.49 (9) NA
Colon cancer 0.65 (2) 2.34 (11) 3.60 (0.8–16.3) .07
NOTE. NA, not available.
a No. of cases per 1000 patient-years.
non-ADMs to be receiving HAART at the time of cancer di-
agnosis (20% vs. 58%; ) and had an overall lowerP ! .0001
median duration of HAART before cancer diagnosis (71.5 days
[range, 0–1708 days] vs. 437 days [range, 0–1485 days]; Pp
) (table 2)..004
There was a gradual decrease in the overall cancer incidence
from 77.05 cases per 1000 patient-years in 1989 to 12.45 cases
per 1000 patient-years in 2002 (figure 1) and from 42.45 cases
per 1000 patient-years in the 1989–1996 period to 21.14 cases
per 1000 patient-years in 1997–2002 (RR, 0.53; 95% CI, 0.41–
0.69) (table 3). The incidence of ADM decreased from 39.91
cases per 1000 patient-years in 1989–1996 to 11.33 cases per
1000 patient-years in 1997–2002 (RR, 0.31; 95% CI, 0.22–0.42).
Conversely, the incidence of non-ADM increased from 3.27
cases per 1000 patient-years to 10.87 cases per 1000 patient-
years (RR, 3.32; 95% CI, 1.69–6.55).
From 1989–1996 to 1997–2002, among patients with ADM,
there was a significant decrease in the incidence of Kaposi sar-
coma (from 27.82 to 5.41 cases per 1000 patient-years; RR,
0.19; 95% CI, 0.12–0.30) and non-Hodgkin lymphoma (from
11.09 to 6.40 cases per 1000 patient-years; RR, 0.58; 95% CI,
0.35–0.94). There was no significant change in the incidence
of cervical cancer (RR, 0.32; 95% CI, 0.05–1.89).
Among the most common non-ADM, there was a significant
increase from 1989–1996 to 1997–2002 in the incidence of skin
cancer (from 0.33 to 3.64 cases per 1000 patient-years; RR,
11.18; 95% CI, 1.5–84.0). There were no cases of anal cancer
during the period of 1989–1996, and there were 9 cases during
the period of 1997–2002 (incidence, 1.49 cases per 1000 patient-
years). There was no significant change in the rate of Hodgkin
disease, and there was a trend toward an increased incidence
of colon cancer (from 0.65 to 2.34 cases per 1000 patient-years;
RR, 3.60; 95% CI, 0.8–16.3).
Discussion. Unlike ADM, no association has been found
between advancing immunosuppression and the development
of non-ADM, with the exception of Hodgkin disease [3, 11,
12]. The pathogenesis of these malignancies is likely to be mul-
tifactorial, with other viral infections (such as human papilloma
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virus [HPV] and Epstein-Barr virus infections) or other high-
risk exposures associated with HIV infection playing a vital
role.
Patients with non-ADM had a significantly higher median
absolute CD4 cell count at the time of diagnosis of cancer than
did those with ADM (276.5 vs. 37.5 cells/mL), but the differ-
ences in nadir CD4 cell count between the 2 groups were much
less marked (78 vs. 22 cells/mL). These findings and those of
other published reports [3] suggest that patients with a history
of profound immunosuppression may no longer be at increased
risk of developing ADM if they experience an immunologic
response to HAART.
Our findings, consistent with previously published data [5,
12, 13], demonstrated significant reductions in the incidence
of Kaposi sarcoma and of non-Hodgkin lymphoma but not in
the incidence of cervical cancer. Conversely, we found an overall
increase in the incidence of non-ADM—specifically, skin and
anal cancer. Although many previously published studies have
not found a significant change in the incidence of these ma-
lignancies between the pre-HAART and HAART eras [5, 10–
12], recent studies have noted a trend towards an increasing
incidence of non-ADM [14]. To date, no associations between
the patients’ CD4 cell count and the risk of acquiring a non-
ADM have been found [10, 12]. These findings suggest that
prolonged exposure to HAART and the attendant reconstitu-
tion of the immune system might not decrease but may, in
fact, increase the risk of non-ADM.
With regard to anogenital malignancies, although we saw no
change in the rates of cervical cancer, we did note a significant
increase in the number of diagnoses of invasive anal cancer
between the pre-HAART era and the HAART era (0 vs. 7 cases).
The disparity between these trends may be explained by the
strict adherence to cervical cancer screening guidelines, in-
cluding at least annual Papanicolaou (Pap) smears, in a single
clinic setting. If anal cancer rates continue to increase, similar
preventive measures (e.g., anal Pap smears) may be warranted.
Our study demonstrated a significant increase in the number
of skin cancer diagnoses between the pre-HAART era and the
HAART era. The large majority of the skin cancers were basal
cell carcinomas, consistent with findings from Lobo et al. [15].
Skin carcinomas are the most common malignant conditions
in transplant recipients [16, 17]. Their incidence is associated
with the level and duration of immunosuppression [17] and is
strongly associated with HPV infection [18]. As in transplant
recipients, persistent HPV infection might lead to a progressive
increase in cases of anogenital and skin cancer in HIV-infected
persons [19].
Finally, we observed a trend toward an increased incidence
of colon cancer. This was not explained by increased screening,
because the policies on colon cancer screening had not changed
in our clinic and the number of colonoscopies performed had
not increased.
Limitations of our study include the relatively small size of
our cohort and the fact that it was drawn from a single site
that may have had specific demographic characteristics, limiting
the generalizability of our results. However, the advantages in-
clude a uniformity in the means of data collection and an
extended follow-up period of up to 13 years. The median age
of patients and the percentage of men who have sex with men
did not significantly change between the pre-HAART and post-
HAART periods. A change in demographic characteristics is
therefore unlikely to explain the trends. Background age-
adjusted skin, colorectal, and anal cancer rates remained con-
stant in Alabama (1, 49, and 1.3 cases per 100,000 patient-
years, respectively) during the observation period [20]. Finally,
the trends in ADM in our cohort were consistent with those
found in other studies, suggesting validity and generalizability
of the non-ADM trends as well.
In summary, these data depict the cancer epidemiology in a
single HIV cohort spanning 13 years and 2 distinct time periods
(the pre-HAART era and the HAART era). They confirm a
decrease in the rate of ADM and signal an increase in the rate
of non-ADM, especially of skin cancer and anal cancer. These
trends are clinically significant and may warrant evaluation of
specific screening interventions, particularly given the expec-
tation of improved survival in this group.
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